AffiliationDepartment of Medicine, Alimentary Pharmabiotic Centre, University College Cork, National University of Ireland, Cork, Ireland. firstname.lastname@example.org
Combined Modality Therapy
Inflammatory Bowel Diseases
Quality of Life
Severity of Illness Index
MetadataShow full item record
CitationThe evolving epidemiology of inflammatory bowel disease. 2009, 25 (4):301-5 Curr. Opin. Gastroenterol.
JournalCurrent opinion in gastroenterology
AbstractAdvances in understanding the basic biology of IBD with rapidly emerging therapeutic strategies have prompted a shift in traditional epidemiologic approaches away from risk factor anthologies toward rapprochement with disease mechanisms and pursuit of changing patterns of comorbidity of clinical relevance.
DescriptionPURPOSE OF REVIEW: Epidemiologic studies in inflammatory bowel disease (IBD) include assessments of disease burden and evolving patterns of disease presentation. Although it is hoped that sound epidemiologic studies provide aetiological clues, traditional risk factor-based epidemiology has provided limited insights into either Crohn's disease or ulcerative colitis etiopathogenesis. In this update, we will summarize how the changing epidemiology of IBD associated with modernization can be reconciled with current concepts of disease mechanisms and will discuss studies of clinically significant comorbidity in IBD. RECENT FINDINGS: The increased frequency of IBD, which has been consistently observed as society becomes developed or modernized, may be linked with changes in the gastrointestinal microbiota which, in turn, may affect the development of the immune system and influence the risk of inflammatory diseases. Although extra-intestinal disease associations have long been recognized to be linked to IBD, there is a disturbing increase in comorbidity with Clostridium difficile-associated disease, arterial and venous thromboembolism and abnormalities of cervical cytology. These have important implications in an era of increased use of immunomodulatory drugs. SUMMARY: Advances in understanding the basic biology of IBD with rapidly emerging therapeutic strategies have prompted a shift in traditional epidemiologic approaches away from risk factor anthologies toward rapprochement with disease mechanisms and pursuit of changing patterns of comorbidity of clinical relevance.
- Impact of Clostridium difficile on inflammatory bowel disease.
- Authors: Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG
- Issue date: 2007 Mar
- The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission.
- Authors: Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP
- Issue date: 2009 May
- Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications.
- Authors: Danese S, Motte Cd Cde L, Fiocchi C
- Issue date: 2004 May
- Inflammatory Bowel Disease and Clostridium difficile-associated diarrhea: a growing problem.
- Authors: Tremaine WJ
- Issue date: 2007 Mar
- Emerging biologic therapies in inflammatory bowel disease.
- Authors: Lim WC, Hanauer SB
- Issue date: 2004 Spring